Really appreciate you taking the time to put this together!
What's particularly notable is the growing body of evidence around cardiovascular benefits. The SELECT trial demonstrated that semaglutide significantly reduced major adverse cardiovascular events in overweight patients without diabetes, suggesting that the benefits of GLP-1 receptor agonist therapy extend well beyond glycemic control and weight loss. Reductions in systemic inflammation, improvements in lipid profiles, and positive effects on blood pressure have all been documented. For patients who carry significant cardiometabolic risk, these incretin-based therapies represent a meaningful step forward in preventive medicine.
GLP-1 receptor agonists have completely transformed the landscape of metabolic medicine over the past decade. Originally developed to manage type 2 diabetes by stimulating insulin secretion in a…
Really appreciate you taking the time to put this together!
What's particularly notable is the growing body of evidence around cardiovascular benefits. The SELECT trial demonstrated that semaglutide significantly reduced major adverse cardiovascular events in overweight patients without diabetes, suggesting that the benefits of GLP-1 receptor agonist therapy extend well beyond glycemic control and weight loss. Reductions in systemic inflammation, improvements in lipid profiles, and positive effects on blood pressure have all been documented. For patients who carry significant cardiometabolic risk, these incretin-based therapies represent a meaningful step forward in preventive medicine.
GLP-1 receptor agonists have completely transformed the landscape of metabolic medicine over the past decade. Originally developed to manage type 2 diabetes by stimulating insulin secretion in a…